| Patient | Elvis Presley |
|---|---|
| Date of birth | 1987-01-08 |
| Identifiers | MRN HR-ML003-SYN; SSN (made up) 000-03-4417 |
| Document date | 2026-08-14 |
| Author | Coleman Ashby-Nakagawa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Mr. Presley is a 39-year-old singer with opioid use disorder on buprenorphine, a benzodiazepine use disorder on a slow diazepam taper, stage 2 hypertension, obesity with prediabetes, obstructive sleep apnea on CPAP, opioid-induced constipation and glaucoma, who comes for his yearly preventive visit one week after his three-week review and five days before a Las Vegas engagement. He has taken buprenorphine 16 mg every morning without withdrawal and with few cravings. He took the first diazepam step, to 36 mg a day, a week ago and noticed only slightly worse sleep for two nights. He took his first tirzepatide dose a week ago and had mild nausea for a day. He uses CPAP most nights and feels more awake in the afternoon. His bowels open every one to two days. He has not had a tetanus booster in more than ten years and has never been tested for HIV or hepatitis. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 39 |
| Buprenorphine | 16 mg daily for four weeks; few cravings |
| Diazepam | 36 mg a day since one week ago |
| Tirzepatide | First 2.5 mg dose a week ago; mild nausea for a day |
| Mood | PHQ-9 5; item 9 scored 0 |
| Medicines | Buprenorphine with naloxone 16 mg daily; diazepam 36 mg a day; amlodipine with valsartan; tirzepatide 2.5 mg weekly; polyethylene glycol; latanoprost; naloxone spray on hand |
Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with him by Dr. Ashby-Nakagawa. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than a month ago |
| Psychosocial | Busy professional life; close friends who work with him; worried about how the engagement will go during treatment |
| Alcohol | None; AUDIT-C 0 |
| Tobacco | Never |
| Other substances | Only the medicines prescribed by this clinic since intake; DAST-10 7 at intake, now in treatment |
| Physical activity | Karate practice twice a week and walks on the grounds most days |
| Nutrition | Moving the main meal earlier; fewer late-night meals |
| Sleep | Seven to eight hours with CPAP; less afternoon sleepiness |
| Safety at home | Feels safe; firearms now locked and unloaded with ammunition separate |
| Road safety | Wears a seat belt; not driving himself until the sleepiness has resolved |
| Activities of daily living | Independent |
| Hearing and vision | Wears tinted glasses for light sensitivity; ophthalmology follow-up planned next month |
| Oral health | Dental visit in the past year |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight down 1.4 kg since intake |
| Eyes | Negative | No eye pain, halos or change in vision |
| Ears, nose, mouth, and throat | Negative | No dry mouth from CPAP |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No cough or breathlessness; snoring stopped on CPAP |
| Gastrointestinal | Positive | Mild nausea for a day after the first tirzepatide dose; bowels every one to two days |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Positive | Occasional neck and back stiffness after practice |
| Integumentary | Negative | No rash or injection-site reaction |
| Neurological | Negative | No tremor, headaches or numbness |
| Psychiatric | Negative | PHQ-9 5; no thoughts of suicide or self-harm; cravings low |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation | Up to five tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation | Up to three tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time | One tablet three times daily; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time | Up to three tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma | Stopped | Oral route | 2026-07-10 to 2026-07-10 | completed | S |
| Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist | One drop in each eye at bedtime | Ophthalmic route | 2026-07-10 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag | One spray for a suspected overdose; call 911 | Nasal route | 2026-07-10 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g in water once daily | Oral route | 2026-07-10 | active | S |
| Senna 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-07-10 to 2026-08-07 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only | Two films once daily, or one film twice daily | Sublingual route | 2026-07-17 | active | S |
| Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable | One tablet four times daily; seven-day supply | Oral route | 2026-07-17 to 2026-08-07 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time | One tablet three times daily with the 2 mg tablets as scheduled | Oral route | 2026-08-07 | active | S |
| Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) | Per the written taper schedule | Oral route | 2026-08-07 to 2026-10-28 | completed | S |
| Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-17 | active | S |
| Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly | 2.5 mg once weekly | Subcutaneous route | 2026-08-07 to 2026-09-23 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-14 | Body height | 183 | cm | S |
| 2026-08-14 | Body weight | 107.6 | kg | S |
| 2026-08-14 | Body mass index (BMI) [Ratio] | 32.1 | kg/m2 | S |
| 2026-08-14 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-08-14 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-08-14 | Heart rate | 74 | /min | S |
| 2026-08-14 | Respiratory rate | 14 | /min | S |
| 2026-08-14 | Body temperature | 36.6 | Cel | S |
| 2026-08-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-14 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-08-14 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 2026-08-14 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 140 | mg/dL | <=129 mg/dL | High | S |
| 2026-08-14 | Triglyceride [Mass/volume] in Serum or Plasma | 180 | mg/dL | <=149 mg/dL | High | S |
Vital signs recorded on 2026-08-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 107.6 kg, BMI 32.1; blood pressure 126/80; pulse 74 |
| Eyes | Pupils equal and reactive; no redness |
| Neck | Circumference 44 cm; no thyroid enlargement |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear |
| Abdomen | Soft, non-tender; liver edge not palpable; no distension |
| Skin | Injection site clean; no track marks |
| Neurological | Normal; no tremor |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | resolved | confirmed | R53.83 | S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses. |
| Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | E66.811 | S — Synthetic modern diagnosis anchored to his documented weight gain. |
| Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | H40.63X1 | S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes. |
| Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers | active | confirmed | F11.20 | S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis. |
| Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives | active | confirmed | F13.20 | S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis. |
| Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension. |
| Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP | active | confirmed | G47.33 | S — Synthetic modern diagnosis from a synthetic sleep study. |
| Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features | active | confirmed | K59.03 | S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 126/80 mmHg on treatment; home average 128/82 |
| Lipid screening and cardiovascular risk | Completed today | Total cholesterol 214, HDL 38, LDL 140, triglycerides 180 mg/dL; low 10-year risk; statin not indicated at 39 |
| Diabetes screening | Up to date | Hemoglobin A1c 5.8% at intake, prediabetes; treated with weight loss |
| Obesity behavioral counseling | Completed today | BMI 32.1; intensive counseling with a dietitian arranged |
| Unhealthy drug use screening | Up to date | DAST-10 7 at intake; in treatment |
| Unhealthy alcohol use | Up to date | AUDIT-C 0 at intake |
| Tobacco use | Not indicated | Never used tobacco |
| Depression screening | Completed today | PHQ-9 5, item 9 scored 0 |
| HIV screening | Ordered | Once for all adults; drawn today with his agreement |
| Hepatitis C screening | Ordered | Once for all adults; drawn today |
| Hepatitis B screening | Ordered | Triple panel once for all adults; drawn today |
| Colorectal cancer screening | Not indicated | Begins at 45 |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap given today; last booster more than ten years ago |
| Hepatitis B vaccine | Due | Recommended for adults 19 to 59; to start once today's serology shows he is not immune |
| Influenza vaccine | Due | When the autumn vaccine is available |
| COVID-19 vaccine | Due | Discussed under shared clinical decision-making; to decide in the autumn |
| Eye examination | Up to date | Under his ophthalmologist's care for glaucoma; next visit next month |
Immunizations given today: Tdap vaccine; last tetanus booster more than ten years ago [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018); Unhealthy Drug Use: Screening (2020); Adult Immunization Schedule by Age (2026)
Follow-up: Las Vegas engagement with weekly video visits; ten-week review after he returns. HIV, hepatitis C and hepatitis B results by phone. Next preventive visit in one year. Next scheduled visit 2026-09-23: ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, a long-time friend who works with him, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being able to sing and to be there for the people who depend on him, and that he would want full treatment, including resuscitation and breathing support, after an overdose or other sudden illness. The plan will be revisited yearly or after any serious illness. [S]